Pancreatic Cancer Research

Clinical trialObservationalCompleted

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia

Outcome
Finished, no results posted
Phase
Observational
Status
Completed
Study type
Observational
Start
28 August 2016
Ended
24 July 2019
Enrollment
253 participants
Sites
1
Primary outcomes
Rate of patients with loss of > 5 % body weight
Sponsor type
Industry
Results posted
No
Last update
7 August 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.

Detailed description public domain (ClinicalTrials.gov)

The PRO Xie project will recruit a representative cohort of patients with advanced lung or advanced pancreatic cancer with a high risk for the development of cancer cachexia. Patient Reported Outcomes (PRO) are assessed in a real life setting by a questionnaire consisting of 20 questions: QoL is measured by SF12, fatigue by FACIT-F and cachexia by FAACT questionnaires, respectively. These data will determine the potential need for anti-cachexia treatment in those patients, as well as the number of underweight patients, the evaluation of general QoL, fatigue and cachexia and the evaluation of malnutrition.